R&D expense · 2012–2025
Avanos Medical R&D expense
$23.3M−11.1% · FY2025
Avanos Medical (AVNS) reported $23.3M in R&D expense for fiscal 2025, −11.1% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $23.3M | −11.1% | Open → |
| FY20242024-12-31 | $26.2M | −3.7% | Open → |
| FY20232023-12-31 | $27.2M | −6.8% | Open → |
| FY20222022-12-31 | $29.2M | −4.6% | Open → |
| FY20212021-12-31 | $30.6M | −12.3% | Open → |
| FY20202020-12-31 | $34.9M | −7.4% | Open → |
| FY20192019-12-31 | $37.7M | −9.8% | Open → |
| FY20182018-12-31 | $41.8M | +9.4% | Open → |
| FY20172017-12-31 | $38.2M | −0.5% | Open → |
| FY20162016-12-31 | $38.4M | +39.1% | Open → |
| FY20152015-12-31 | $27.6M | −17.9% | Open → |
| FY20142014-12-31 | $33.6M | −11.3% | Open → |
| FY20132013-12-31 | $37.9M | +14.8% | Open → |
| FY20122012-12-31 | $33.0M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2012–2025 compound annual growth −2.6%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Avanos Medical R&D expense |url=https://companiesranked.com/en/company/avanos-medical/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Avanos Medical R&D expense. CompaniesRanked. https://companiesranked.com/en/company/avanos-medical/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-avanos-medical-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Avanos Medical R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/avanos-medical/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001606498-26-000004 · February 24, 2026
{{cite web |title=Avanos Medical R&D expense — 10-K (0001606498-26-000004) |url=https://www.sec.gov/Archives/edgar/data/1606498/000160649826000004/avns-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.